Article Text

Download PDFPDF
A treatable hypertrophic neuropathy
  1. Marcus V Pinto1,
  2. Robert J Spinner2,
  3. Nathan P Staff1
  1. 1 Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA
  2. 2 Department of Neurosurgery, Mayo Clinic, Rochester, Minnesota, USA
  1. Correspondence to Dr Nathan P Staff, Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA; staff.nathan{at}mayo.edu

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Case

A 42-year-old woman was referred to our institution with 5 years of progressive proximal and distal weakness, distal paresthesia in lower and upper limbs, severe shocking pain radiating from the neck and lumbar spine to upper and lower limbs, and voice hoarseness. She had previously been diagnosed with multiple plexiform neurofibromas after imaging studies had shown marked nerve hypertrophy. She had no relevant family history. On examination, there was a severe tetraparesis (2/5 distal and 3/5 proximal lower limbs; 4/5 upper limbs), absent reflexes throughout, absent plantar reflexes, stocking and glove sensation loss to all modalities, bilateral foot drop, steppage gait assisted by a walker, a positive Romberg’s sign and no stigmata of neurofibromatosis type 1.

Nerve conduction studies and electromyography showed very slow ulnar motor conduction velocity at 7 m/s, a compound muscle action potential amplitude of 0.2 mV and distal motor latency of 18 ms. Her left R1 blink response was very prolonged at 19.2 ms. Cerebrospinal fluid protein was 0.73 g/L (0.15–0.45), cell count 2/µL …

View Full Text

Footnotes

  • Contributors MVP: data collection, drafting of final manuscript, approval and critical review of final form. RJS: data collection, approval and critical review of final form. NPS: data collection, drafting of final manuscript, approval and critical review of final form.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned. Externally peer reviewed by Gareth Llewelyn, Cardiff, UK and Simon Rinaldi, London, UK.

Other content recommended for you